Items per page
Sort by

Send to:

Choose Destination

Results: 6

Related Articles by Review for PubMed (Select 20404007)


Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.

Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO, Horwitz SB.

Clin Cancer Res. 2010 Jun 1;16(11):2999-3010. doi: 10.1158/1078-0432.CCR-09-3233. Epub 2010 Apr 19.


Targeting the insulin growth factor receptor 1.

Arnaldez FI, Helman LJ.

Hematol Oncol Clin North Am. 2012 Jun;26(3):527-42, vii-viii. doi: 10.1016/j.hoc.2012.01.004. Epub 2012 Feb 28. Review.


Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum.

Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ, Tsang BK.

Ann N Y Acad Sci. 2012 Oct;1271:58-67. doi: 10.1111/j.1749-6632.2012.06734.x. Review. Erratum in: Ann N Y Acad Sci. 2013 Sep;1299:100.


Insulin/Insulin-like growth factors in cancer: new roles for the aryl hydrocarbon receptor, tumor resistance mechanisms, and new blocking strategies.

Salisbury TB, Tomblin JK.

Front Endocrinol (Lausanne). 2015 Feb 2;6:12. doi: 10.3389/fendo.2015.00012. eCollection 2015. Review.


Oncogenes associated with drug resistance in ovarian cancer.

Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F.

J Cancer Res Clin Oncol. 2015 Mar;141(3):381-95. doi: 10.1007/s00432-014-1765-5. Epub 2014 Jul 6. Review.


Nature as a remarkable chemist: a personal story of the discovery and development of Taxol.

Wani MC, Horwitz SB.

Anticancer Drugs. 2014 May;25(5):482-7. doi: 10.1097/CAD.0000000000000063. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk